Skip to content

FDA Dataset Helps Firms Scrutinize Third-Party Chemistry Labs

Medical devices that contact the human body undergo biocompatibility safety assessments prior to market release, including tests for physiochemical properties.  The Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) recently released a dataset to assist medical device firms in this process.  The information addresses capabilities of third-party analytical chemistry labs.   The CDRH release that accompanied the dataset explains that one option for biocompatibility testing is non-targeted extraction studies to detect and quantify chemicals that may be leached by a medical device during use, followed by a toxicological risk assessment (TRA) to determine whether any of the chemicals identified in the study are unsafe. According to the CDHR release, the overall quality of the TRA is therefore “dependent on the sensitivity of the analytical chemistry method used to detect and quantify chemicals that may be present following extraction from a medical device.”

The CDRH dataset helps to increase the consistency and transparency of biocompatibility assessment methods by providing a characterization by gas chromatography of more than 100 chemicals having a broad range physiochemical properties. This characterization includes the Relative Response Factor (RRF) for each chemical, which is a way of characterizing the detectability of chemicals. A showing that the detectability of chemicals across a broad range physiochemical properties by an analytical chemistry lab is similar to the detectability of chemicals by the CDRH increases the confidence that the lab identified all relevant chemicals in the study.

The CDRH dataset follows an FDA Letter released earlier this year reporting on an alarming trend showing that an increasing number of third-party test labs generate fabricated, duplicated, or otherwise unreliable testing data. As Knobbe has previously discussed, the FDA Letter further warns that “it is incumbent on device firms to take proactive steps to qualify third-party labs and to closely scrutinize all testing data that a firm itself does not perform, especially relating to biocompatibility and other testing.” Tools like the CDRH dataset may offer firms one basis for such scrutiny.


, ,

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal